---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-022428"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:12:44.179069+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Relmada Q4 net loss $37.9M; cash at $148.3M; plans revised REL-1017 MDD trials after Study 301 failure

## Summary
- Q4 2022 net loss $37.9M ($1.28/diluted share), vs $34.4M ($1.80) in Q4 2021; full-year net loss $157.0M.
- Cash and short-term investments $148.3M at Dec 31, 2022, down from $211.9M a year earlier.
- Will amend ongoing Phase 3 Study 302 and initiate new Study 304 for REL-1017 as adjunctive MDD treatment.
- Appointed Cedric O'Gorman, M.D. as CMO and Fabiana Fedeli as independent board director.
- Study 302 enrollment expected H1 2024; Study 304 to start mid-2023 with data in H2 2024.

## SEC filing metadata
- accession: 0001213900-23-022428
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390023022428/0001213900-23-022428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390023022428/ea175642-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-022428
- JSON: https://secwatch.observer/filing/0001213900-23-022428.json
- Plain text: https://secwatch.observer/filing/0001213900-23-022428.txt

## Key facts
- Earnings Releases
  RELMADA THERAPEUTICS, INC. reported for the year ended December 31, 2022 results: net income -$157.0 million, EPS -$5.30.
  - Period: for the year ended December 31, 2022
  - Net income: -$157.0 million
  - EPS: -$5.30
  - Result: preliminary results
  source text: Net loss for the year ended December 31, 2022 and 2021 was $157.0 million and $125.8 million, respectively. The Company had a net loss of $5.30 and $7.16 per share for the year ended December 31, 2022 and 2021, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390023022428/0001213900-23-022428-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.